Axsome Therapeutics
AXSM
176 hedge funds and large institutions have $1.51B invested in Axsome Therapeutics in 2021 Q2 according to their latest regulatory filings, with 24 funds opening new positions, 67 increasing their positions, 50 reducing their positions, and 31 closing their positions.
34% more repeat investments, than reductions
Existing positions increased: 67 | Existing positions reduced: 50
15% more capital invested
Capital invested by funds: $1.31B → $1.51B (+$200M)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
2.09% less ownership
Funds ownership: 61.62% → 59.54% (-2.1%)
4% less funds holding
Funds holding: 184 → 176 (-8)
23% less first-time investments, than exits
New positions opened: 24 | Existing positions closed: 31
53% less call options, than puts
Call options by funds: $28.4M | Put options by funds: $60.4M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PA
Perceptive Advisors
New York
|
+$33.2M |
| 2 |
BG
Bellevue Group
Kuesnacht,
Switzerland
|
+$21.1M |
| 3 |
Morgan Stanley
New York
|
+$10.5M |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$9.63M |
| 5 |
N
Nuveen
Charlotte,
North Carolina
|
+$9.58M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AllianceBernstein
Nashville,
Tennessee
|
-$36M |
| 2 |
Janus Henderson Group
London,
United Kingdom
|
-$12M |
| 3 |
BlackRock
New York
|
-$11.9M |
| 4 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$11.3M |
| 5 |
Two Sigma Investments
New York
|
-$9.16M |
AXSM Hedge Fund Activity: Q2 2021 in Review
176 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in Axsome Therapeutics (AXSM) for Q2 2021, worth a combined $1.51B — up 15% from $1.31B a quarter earlier.
Sellers outnumbered buyers: 31 funds closed out of AXSM and 24 opened new positions — a net loss of 7 holders — while 50 trimmed existing stakes and 67 added.
The largest buyer was Perceptive Advisors, opening a new position worth an estimated $33.2M. The largest seller was AllianceBernstein, cutting an estimated $36M.
- 176 institutional investors held Axsome Therapeutics (AXSM) as of Q2 2021, down from 184 in Q1 2021.
- Funds reported $1.51B of Axsome Therapeutics stock for Q2 2021, up 15% quarter-over-quarter.
- 24 funds opened new Axsome Therapeutics positions in Q2 2021 and 31 closed out, a net change of -7 holders.
- The largest Axsome Therapeutics buyer in Q2 2021 was Perceptive Advisors, an estimated $33.2M added.
- The largest Axsome Therapeutics seller in Q2 2021 was AllianceBernstein, an estimated $36M sold.
Based on aggregated 13F filings for Q2 2021.